Reset filter
Mots-clés
Neoplasm, Liver ×
Afficher plus Mots-clés
Table des matières
  1. 1. Essai clinique
  2. 2. Routinedokumentation
  3. 3. Études de registres/cohortes
  4. 4. Assurance qualité
  5. 5. Standard de données
  6. 6. Questionnaire pour les patients
  7. 7. Spécialité médicale
Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

98 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Liver Cancer NCT02424955

- 29/06/2020 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation; ODM derived from: https://clinicaltrials.gov/show/NCT02424955

Eligibility Hepatic Cancer NCT00923052

- 08/06/2020 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Criteria
The Natural History of Solid Organ Cancer Stem Cells (SOCSC); ODM derived from: https://clinicaltrials.gov/show/NCT00923052

Treatment Form Liver Cancer CALGB 80802

- 03/01/2015 - 1 Formulaire, 2 Groupes Item, 32 Eléments de données, 1 Langue
Groupes Item: Header Module, Treatment Data
CALGB: 80802 Treatment Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer NCT01015833 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A6270-CE1B-C531-E040-BB89AD431F2C

dbGaP phs000942 Use of WGS for Diagnosis and Discovery in the Cancer Genetics Clinic - Eligibility

- 27/11/2024 - 5 Formulaires, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: IG.elig
Principal Investigator: Theodora S. Ross, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA, and Department of Cancer Genetics, UT Southwestern Medical Center, Dallas, TX, USA MeSH: Neoplasms,Breast Neoplasms,Ovarian Neoplasms,Peritoneal Neoplasms,Skin Neoplasms,Esophageal Neoplasms,Thyroid Neoplasms,Urinary Bladder Neoplasms,Endometrial Neoplasms,Fallopian Tube Neoplasms,Melanoma,Testicular Neoplasms,Bile Duct Neoplasms,Lung Neoplasms,Colonic Neoplasms,Adrenocortical Carcinoma,Carcinoma, Renal Cell,Colonic Polyps,Adenomatous Polyposis Coli,Lymphoma, Large B-Cell, Diffuse,Pheochromocytoma,Paraganglioma,Leiomyoma,Hemangioblastoma,Hyperparathyroidism,Pancreatic Neoplasms,Vulvar Neoplasms,Brain Neoplasms,Liver Neoplasms,Kidney Neoplasms,Prostatic Neoplasms,Glioblastoma,Oncocytoma, renal https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000942 Despite the potential of whole-genome sequencing (WGS) to improve patient diagnosis and care, the empirical value of WGS in the cancer genetics clinic is unknown. We performed WGS on members of two cohorts of cancer genetics patients: those with BRCA1/2 mutations (n = 176) and those without (n = 82). Initial analysis of potentially pathogenic variants (PPVs, defined as nonsynonymous variants with allele frequency 1% in ESP6500) in 163 clinically-relevant genes suggested that WGS will provide useful clinical results. This is despite the fact that a majority of PPVs were novel missense variants likely to be classified as variants of unknown significance (VUS). Furthermore, previously reported pathogenic missense variants did not always associate with their predicted diseases in our patients. This suggests that the clinical use of WGS will require large-scale efforts to consolidate WGS and patient data to improve accuracy of interpretation of rare variants. While loss-of-function (LoF) variants represented only a small fraction of PPVs, WGS identified additional cancer risk LoF PPVs in patients with known BRCA1/2 mutations and led to cancer risk diagnoses in 21% of non-BRCA cancer genetics patients after expanding our analysis to 3209 ClinVar genes. These data illustrate how WGS can be used to improve our ability to discover patients' cancer genetic risks. "Reprinted from doi:10.1016/j.ebiom.2014.12.003, with permission from EBioMedicine."

pht004834.v1.p1

1 Groupe Item 5 Eléments de données

pht004835.v1.p1

1 Groupe Item 5 Eléments de données

pht004836.v1.p1

1 Groupe Item 16 Eléments de données

pht004837.v1.p1

1 Groupe Item 5 Eléments de données

Liver Cancer NCT01015833 On-Study - CALGB 80802 On-Study Form - 2940677v1.0 - CALGB 80802 On-Study Form

- 20/09/2021 - 1 Formulaire, 6 Groupes Item, 49 Eléments de données, 1 Langue
Groupes Item: Header Module, Patient Description, Prior Treatment, Required Lab Values, Child Pugh Classification, Footer Module
CALGB 80802 On-Study Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=73B6D8AE-497C-7324-E040-BB89AD43648A

Liver Cancer NCT01015833 Registration - CALGB 80802 Registration Worksheet Form - 2940585v1.0 - CALGB 80802 Registration Worksheet Form

- 17/09/2021 - 1 Formulaire, 10 Groupes Item, 45 Eléments de données, 1 Langue
Groupes Item: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Optional Companion Studies, Registration Information, Notes
CALGB 80802 Registration Worksheet Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=73B6D8AE-48AF-7324-E040-BB89AD43648A

Liver Cancer NCT01004978 Eligibility - E1208 Registration Worksheet/Step 1 - 2944998v1.0 - E1208 Registration Worksheet/Step 1

- 17/09/2021 - 1 Formulaire, 3 Groupes Item, 29 Eléments de données, 1 Langue
Groupes Item: Eligibility, Demographic Data Required For Patient Registration, I have reviewed the above data and agree the date are accurate and correct
E1208 Registration Worksheet/Step 1 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7454791C-AC85-65C0-E040-BB89AD431786

Liver Cancer NCT01015833 Lab - CALGB: 80802 Sample Submission Form - 2943746v1.0 - CALGB: 80802 Sample Submission Form

- 09/01/2015 - 1 Formulaire, 4 Groupes Item, 25 Eléments de données, 1 Langue
Groupes Item: Header Module, Module 2, Shipping Information, Footer Module
CALGB: 80802 Sample Submission Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741BA0BF-5B36-06EF-E040-BB89AD434B15

Liver Cancer NCT01015833 Response - CALGB: 80802 Follow-Up and Response Form - 2943577v1.0 - CALGB: 80802 Follow-Up and Response Form

- 08/01/2015 - 1 Formulaire, 5 Groupes Item, 28 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, Vital Status, Response Data, Footer
CALGB: 80802 Follow-Up and Response Form Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=741A9174-BCA1-70FC-E040-BB89AD436A0F

Liver Cancer NCT01015833 On-Study - CALGB Solid Tumor Evaluation Form (RECIST 1.1) - 2946223v1.0 - CALGB Solid Tumor Evaluation Form (RECIST 1.1)

- 09/01/2015 - 1 Formulaire, 7 Groupes Item, 35 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, Report Period, TARGET LESIONS, Comments, NON-TARGET LESIONS, Footer Module
CALGB Solid Tumor Evaluation Form (RECIST 1.1) Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=746D8651-FF47-E158-E040-BB89AD4366AF

Liver Cancer NCT01004978 Follow-Up - E1208 Long-Term Follow-up Form - 2926924v1.0 - E1208 Long-Term Follow-up Form

- 08/01/2015 - 1 Formulaire, 9 Groupes Item, 34 Eléments de données, 1 Langue
Groupes Item: Header Module, Header, Section I - Vital Status, Section II - Reporting Period, Section III - Notice of New Primary, Section IV - Disease Follow-up Status, Section V - Adverse Events, Section VI - Non-Protocol Therapy Prior To Progression, Footer Module
E1208 Long-Term Follow-up Form Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=705708B9-0164-E0FE-E040-BB89AD435F94

Eligibility Liver Metastases NCT01763450

- 01/07/2020 - 1 Formulaire, 2 Groupes Item, 23 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01763450

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial